Rosuvastatin May Reduce the Incidence of Cardiovascular Events in Patients with Acute Coronary Syndromes Receiving Percutaneous Coronary Intervention by Suppressing miR‐155/SHIP‐1 Signaling Pathway. Issue 6 (December 2014)

• Record Type: Journal Article
• Authors: Xie, Wenchao; Li, Ping; Wang, Zhengdong; Chen, Jian; Lin, Zhihai; Liang, Xiangwen; Mo, Yingxi
• Is Part Of: Cardiovascular therapeutics. Volume 32:Issue 6(2014:Dec.)
• Page Start: 276
• Page End: 282
• Publication Date: 2014-12
• Subjects: Cardiovascular pharmacology -- Periodicals; Cardiovascular agents -- Periodicals; Cardiovascular system -- Diseases -- Chemotherapy -- Periodicals; Cardiovascular Agents -- Periodicals; Cardiovascular Diseases -- drug therapy -- Periodicals; Agents cardiovasculaires -- Périodiques; Appareil cardiovasculaire -- Maladies -- Chimiothérapie -- Périodiques; 616.1005
• DOI: 10.1111/1755-5922.12098
• Languages: English
• ISSNs: 1755-5914

Abstract

<abstract abstract-type="main" id="cdr12098-abs-0001"> <title>Summary</title> <sec id="cdr12098-sec-0001" sec-type="section"> <title>Purpose</title> <p>The beneficial effect of rosuvastatin against percutaneous coronary intervention (PCI) related procedural myocardial injury has been determined mostly in patients with acute coronary syndromes (ACS). However, the detailed therapeutic mechanism has not been well studied.</p> </sec> <sec id="cdr12098-sec-0002" sec-type="section"> <title>Methods</title> <p>Patients with ACS receiving PCI (n = 159) were randomized to control group (placebo treatment) or to rosuvastatin group (20 mg 12 h before PCI, and a further 20 mg 2 h preprocedure dose). Levels of INF‐<italic>γ</italic>, TNF‐<italic>α</italic>, IL‐6, miR‐155/SHIP‐1, and CD4<sup>+</sup>FoxP3<sup>+</sup>Treg in peripheral blood were detected before PCI and 24 h after PCI. Clinical data of these patients were also collected in this prospective study.</p> </sec> <sec id="cdr12098-sec-0003" sec-type="section"> <title>Results</title> <p>Compared with placebo, rosuvastatin treatment significantly reduced the incidence of periprocedural myocardial infarction (PMI) and levels of cardiac troponin I (cTnI) associated with decreased relative expression of serum miR‐155, levels of inflammatory cytokines (INF‐<italic>γ</italic>, TNF‐<italic>α</italic>, and IL‐6), increased SHIP‐1 expression and CD4<sup>+</sup>FoxP3<sup>+</sup>Treg percentage values (<italic>P </italic><<italic> </italic>0.05). In addition, patients with rosuvastatin pretreatment also reduced incidence of 30 days major adverse cardiac events (MACE) compared to the patients with placebo treatment (16 patients vs. 28 patients, <italic>P </italic>=<italic> </italic>0.038).</p> </sec> <sec id="cdr12098-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Our study suggests that high loading dose rosuvastatin pretreatment may reduce the incidence of cardiovascular events and levels of inflammatory markers in patients with ACS receiving PCI, which may be explained at least in part, by mechanism involving suppression of miR‐155/SHIP‐1 signaling pathway.</p> </sec> </abstract>